Hyaluronan dermal fillers via crosslinking with 1,4-butandiol diglycidyl ether: Exploitation of heterogeneous reaction conditions

被引:25
作者
La Gatta, Annalisa [1 ]
Papa, Agata [1 ]
Schiraldi, Chiara [1 ]
De Rosa, Mario [1 ]
机构
[1] Univ Naples 2, Fac Med, Dept Expt Med, I-80138 Naples, Italy
关键词
hyaluronan; crosslinking; dermal filler; enzymatic degradation; injectable gels; PHYSICAL-PROPERTIES; ACID; HYDROGELS; CELLULOSE; CHITOSAN;
D O I
10.1002/jbm.b.33329
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Most of hyaluronan (HA)-based dermal fillers currently available on the market are produced through biopolymer crosslinking with 1,4-butandiol diglycidyl ether (BDDGE). Chemical modification is usually performed on the biopolymer dissolved in a highly alkaline aqueous medium (homogeneous conditions). Heterogeneous conditions for HA reaction with BDDGE were exploited here to obtain competitive HA fillers and to assess potential improvements in production process. Optimal parameters for effective reaction accomplishment were evaluated (e.g., medium composition, temperature and time of reaction). HA was modified with increasing BDDGE/HA equivalents (7-14%) achieving 66-74% (w/w) biopolymer insolubility. Hydrogels exhibited high swelling extent and outstanding resistance to enzymatic degradation decreasing and improving according to crosslinking degree, respectively. Once suspended in physiological solution (20 mg/mL), these products directly formed easy-to-extrude gels through 27-29 G needles. Gel particle dimensions were in the range 10-1000 mu m. Rheological analyses revealed decreasing viscosity with the shear rate and G values in the range 1200-1700 Pa. Overall, results of the in vitro characterization demonstrated the attainment of crosslinked HA particles suitable for application as dermal fillers. These new gels proved superior to similar commercialized products in terms of stability to enzymatic hydrolysis. Further, the protocol assessed allowed interesting improvements over conventional manufacturing procedures. (c) 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 9-18, 2016.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 43 条
[1]  
Agerup B., 1998, Polysaccharide gel composition, Patent No. [US5827937A, 5827937, USP 5827937]
[2]  
Allemann IB, 2008, CLIN INTERV AGING, V3, P629
[3]   Hyaluronic acid and its use as a "rejuvenation" agent in cosmetic dermatology [J].
Andre, P .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2004, 23 (04) :218-222
[4]   Novel synthetic dermal fillers based on sodium carboxymethylcellulose: Comparison with crosslinked hyaluronic acid-based dermal fillers [J].
不详 .
DERMATOLOGIC SURGERY, 2007, 33 (02) :S136-S143
[5]   Hyaluronic Acid Fillers: A Comprehensive Review [J].
Beasley, Karen L. ;
Weiss, Margaret A. ;
Weiss, Robert A. .
FACIAL PLASTIC SURGERY, 2009, 25 (02) :86-94
[6]   A MODIFIED URONIC ACID CARBAZOLE REACTION [J].
BITTER, T ;
MUIR, HM .
ANALYTICAL BIOCHEMISTRY, 1962, 4 (04) :330-&
[7]   Interpenetrating polymer network (IPN) scaffolds of sodium hyaluronate and sodium alginate for chondrocyte culture [J].
Chung, Chung-Wook ;
Kang, Jeong Yeon ;
Yoon, In-Soo ;
Hwang, Hyung-Don ;
Balakrishnan, Prabagar ;
Cho, Hyun-Jong ;
Chung, Kyu-Don ;
Kang, Dae-Hwan ;
Kim, Dae-Duk .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2011, 88 (02) :711-716
[8]  
D'Este M, 2011, Patent No. [WO 2011/023355 A2, 2011023355]
[9]  
Dastoor Sarosh F, 2007, J Oral Implantol, V33, P191, DOI 10.1563/1548-1336(2007)33[191:DFFFST]2.0.CO
[10]  
2